Clinical Trials
19 trialsNCT05186753 2026-05-22
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT04662255 2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05833438 2026-05-01
VENAZA-5S
University of Leipzig
Phase 2 Active not recruiting
NCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05317416 2026-04-16
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04761770 2026-02-17
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03842696 2026-01-27
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT07364409 2026-01-23
ReSTORE
Herlev and Gentofte Hospital
Phase NA Active not recruiting
NCT05023980 2026-01-22
BRUIN CLL-313
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01352520 2026-01-20
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04062266 2026-01-13
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04572815 2026-01-02
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT06849921 2025-02-27
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
Ruijin Hospital
Phase NA Active not recruiting
NCT04786028 2025-01-08
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
Canadian Myeloma Research Group
Phase 2 Active not recruiting